Fulgent Genetics Inc reports results for the quarter ended in December - Earnings Summary

Fulgent Genetics

28/02/2023 22:51

* Fulgent Genetics Inc  FLGT.OQ  reported a quarterly
adjusted
loss of 48 cents​​ per share for the quarter ended in December.
The mean expectation of three analysts for the quarter was for a
loss of 56 cents per share.
    * Revenue fell 73.1% to $67.70 million from a year ago;
analysts
expected $59.57 million. 
    * Fulgent Genetics Inc's reported EPS for the quarter was a
loss
of 80 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Fulgent Genetics Inc shares had risen by 9.7% this
quarter.
    * The company reported a quarterly loss of $23.83 million.
    * Wall Street's median 12-month price target for Fulgent
Genetics
Inc is $45.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
28 at 10:51 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.56          -0.48          Beat
 Sep. 30 2022      0.05           0.32           Beat
 Jun. 30 2022      0.73           0.78           Beat
 Mar. 31 2022      3.86           5.08           Beat